195 related articles for article (PubMed ID: 25048051)
21. Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma.
Gröbe A; Eichhorn W; Fraederich M; Kluwe L; Vashist Y; Wikner J; Smeets R; Simon R; Sauter G; Heiland M; Blessmann M
J Oral Pathol Med; 2014 Mar; 43(3):205-10. PubMed ID: 24020871
[TBL] [Abstract][Full Text] [Related]
22. Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal.
Miller DD; Emley A; Yang S; Richards JE; Lee JE; Deng A; Hoang MP; Mahalingam M
Mod Pathol; 2012 Apr; 25(4):505-15. PubMed ID: 22157936
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic molecular markers in oral and lip squamous cell carcinoma--evaluation of expression and its significance].
Jaworska M; Kołosza Z; Liszka J; Nikiel B; Goleń M; Lange D; Scierski W; Namysłowski G
Otolaryngol Pol; 2008; 62(2):175-81. PubMed ID: 18637442
[TBL] [Abstract][Full Text] [Related]
24. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
25. p53 and PCNA expression in malignant melanomas of the head and neck.
Girod SC; Groth W; Junk M; Gerlach KL
Pigment Cell Res; 1994 Oct; 7(5):354-7. PubMed ID: 7886008
[TBL] [Abstract][Full Text] [Related]
26. Expression of Ki-67 and p53 in cutaneous free flaps used to reconstruct soft tissue defects following resection of oral squamous cell carcinoma.
Max Robinson C; Prime SS; Paterson IC; Guest PG; Eveson JW
Oral Oncol; 2007 Mar; 43(3):263-71. PubMed ID: 16920383
[TBL] [Abstract][Full Text] [Related]
27. The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma.
Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Tomoyose T; Takano H; Funaki K; Fukuyama H; Takahashi T; Sakoda S
J Oral Pathol Med; 2005 Nov; 34(10):602-7. PubMed ID: 16202080
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
[TBL] [Abstract][Full Text] [Related]
29. Head and neck squamous cell carcinoma in non-smoking and non-drinking patients with multiple tumors: etiologic significance of p53 and Ki-67 in non-tumorous epithelium.
Farshadpour F; Hordijk GJ; Koole R; Slootweg PJ
J Oral Pathol Med; 2008 Oct; 37(9):549-54. PubMed ID: 18331287
[TBL] [Abstract][Full Text] [Related]
30. MCM3 could be a better marker than Ki-67 for evaluation of dysplastic oral lesions: an immunohistochemical study.
Lameira AG; Pontes FS; Guimarães DM; Alves AC; de Jesus AS; Pontes HA; Pinto Ddos S
J Oral Pathol Med; 2014 Jul; 43(6):427-34. PubMed ID: 24456424
[TBL] [Abstract][Full Text] [Related]
31. Prognostic importance of mitochondrial markers in mucosal and cutaneous head and neck melanomas.
Soares CD; Morais TML; Carlos R; de Almeida OP; Mariano FV; Altemani A; de Carvalho MGF; Corrêa MB; Dos Reis RRD; Amorim LS; Jorge J
Hum Pathol; 2019 Mar; 85():279-289. PubMed ID: 30468799
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical characteristics of melanoma.
Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
[TBL] [Abstract][Full Text] [Related]
33. The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers.
Björk-Eriksson T; West CM; Cvetskovska E; Svensson M; Karlsson E; Magnusson B; Slevin NJ; Edström S; Mercke C
Br J Cancer; 1999 Jul; 80(9):1400-4. PubMed ID: 10424742
[TBL] [Abstract][Full Text] [Related]
34. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck.
Morris LG; Wen YH; Nonaka D; DeLacure MD; Kutler DI; Huan Y; Wang BY
Head Neck; 2008 Jun; 30(6):771-5. PubMed ID: 18228523
[TBL] [Abstract][Full Text] [Related]
35. Comparative distribution of S-100 protein and antigen HMB-45 in various types of melanomas and naevi.
Mirecka J; Korabiowska M; Schauer A
Pol J Pathol; 1995; 46(3):167-72. PubMed ID: 7496736
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
[TBL] [Abstract][Full Text] [Related]
37. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas.
Richmond-Sinclair NM; Lee E; Cummings MC; Williamson R; Muller K; Green AC; Hayward NK; Whiteman DC
Melanoma Res; 2008 Oct; 18(5):336-45. PubMed ID: 18781132
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance.
Loggini B; Rinaldi I; Pingitore R; Cristofani R; Castagna M; Barachini P
Tumori; 2001; 87(3):179-86. PubMed ID: 11504374
[TBL] [Abstract][Full Text] [Related]
39. Reliability of immunostaining using pan-melanoma cocktail, SOX10, and microphthalmia transcription factor in confirming a diagnosis of melanoma on fine-needle aspiration smears.
Clevenger J; Joseph C; Dawlett M; Guo M; Gong Y
Cancer Cytopathol; 2014 Oct; 122(10):779-85. PubMed ID: 24954720
[TBL] [Abstract][Full Text] [Related]
40. Multiple primary melanomas versus single melanoma of the head and neck: a comparison of genetic, diagnostic, and therapeutic implications.
Pollio A; Tomasi A; Pellacani G; Ruini C; Mandel VD; Fortuna G; Seidenari S; Ponti G
Melanoma Res; 2014 Jun; 24(3):267-72. PubMed ID: 24638154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
